Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

Nuckols VR, Barone Gibbs B, Brewer BC, Gaffey AE, Greaney JL, Patterson F, Greenland P, Saade GR, Grobman WA, Yee LM, Bairey Merz CN, Chung[...]

Bellouni G, Clanet M, Touihri K, Delaporte A, Boulos NM, Kim K, Grogan T, Alexander B, Coeckelenbergh S, Joosten A. Incidence and predictors of postoperative[...]

Dermenchyan A, Seiden DS, Bhayani M, Song A, Venkatesan N, Sharma K, Pandrangi K, Han MA. From Insight to Impact: Advancing Learning Health System Capability[...]